The latter is of particular interest given that the hippocampal complex is considered to be one of the primary targets for AD therapies.ĭiscussion: This work introduces a possible improvement strategy for GENUS therapy that might contribute to increasing the efficacy of the therapy or shortening the time needed for the positive outcome.Īlzheimer disease's (AD) is a progressive, life-shortening condition characterized by a gradual decline in cognitive abilities, eventually leading to dementia ( Breijyeh and Karaman, 2020 Knopman et al., 2021). Results: We found that the inclusion of a cognitive task during the GENUS session not only has a positive effect on the strength and extent of the gamma entrainment, but also promotes the propagation of gamma entrainment to additional neural areas including deep ones such as hippocampus which were not recruited when no cognitive task was required from the participants. All participants completed several GENUS sessions, in each of which a different cognitive task was performed. Methods: We recruited a cohort of 15 participants who underwent a scalp-EEG recording as well as one epilepsy patient who was implanted with 50 subdural surface electrodes over temporo-occipital and temporo-basal cortex and 14 depth contacts that targeted the hippocampus and insula. The current work hypothesizes that the varying success in humans is due to differences in cognitive workload during the GENUS sessions. While this has shown to be effective in animal models, studies on human participants have reported varying success. One particular promising non-pharmacological therapy that has received increased attention in recent years is based on the Gamma ENtrainment Using Sensory stimulation (GENUS), a high-frequency neural response elicited by a visual and/or auditory stimulus at 40 Hz.
Introduction: Alzheimer's disease is one of the great challenges in the coming decades, and despite great efforts, a widely effective disease-modifying therapy in humans remains elusive.
6Department of Neurosurgery, Ghent University Hospital, Ghent, Belgium.5Department of Neuroscience, Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.4Leuven Brain Institute (LBI), Leuven, Belgium.3Department of Neuroscience, Laboratory for Neuro- and Psychophysiology, KU Leuven, Leuven, Belgium.2Department of Neurology, General Hospital Maria Middelares, Ghent, Belgium.1Department of Neurology, Ghent University Hospital, Ghent, Belgium.Elvira Khachatryan 1,2,3 *, Benjamin Wittevrongel 3,4, Mariska Reinartz 4,5, Ine Dauwe 1, Evelien Carrette 1, Alfred Meurs 1, Dirk Van Roost 6, Paul Boon 1 and Marc M.
0 kommentar(er)
